Trends in Immunotherapy

Article

Therapeutic modulation of neuroinflammatory and apoptotic pathways by PEPITEM in an EAE model of multiple sclerosis

Downloads

https://doi.org/10.24294/ti.v8.i2.6879
Alassiri, M. (2024). Therapeutic modulation of neuroinflammatory and apoptotic pathways by PEPITEM in an EAE model of multiple sclerosis. Trends in Immunotherapy, 8(2). https://doi.org/10.24294/ti.v8.i2.6879
Volume 8 Issue 2 (2024)
Copyright (c) 2024 Mohammed Alassiri
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Mohammed Alassiri
    Department of Basic Sciences, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS); King Abdullah International Medical Research Center (KAIMRC); Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City (KAMC).

Objective: To examine the therapeutic effects of PEPITEM on neuroinflammatory and apoptotic pathways in an Experimental Autoimmune Encephalomyelitis (EAE) model of Multiple Sclerosis (MS), focusing on the modulation of key biomarkers: SIRT1, NRF2, NF-κB p65, Bax, and Bcl2. Methods: We utilized a controlled experimental design involving five groups of female C57BL/6 mice, aged 9–12 months to assess the effects of PEPITEM administered therapeutically and prophylactically. Groups included a normal healthy mice group (G1), an EAE-induced group receiving scrambled peptide therapeutically (post-induction) (G2), an EAE-induced group treated with PEPITEM therapeutically (G3), and an EAE-induced group given scrambled peptide (G4) prophylactically or, an EAE-induced group treated with PEPITEM prophylactically (G5). Following induction and PEPITEM treatment, weight and EAE scores were compared among the designated groups. Additionally, spinal cord tissues were harvested for protein lysate preparation and Western blot analysis quantified the expression levels of the selected biomarkers. Results: Analysis of the weight and EAE scores reveals that G3 and G5 exhibit trends toward recovery, potentially indicating the effectiveness of the treatment. Moreover, PEPITEM treatment significantly upregulated the expression of SIRT1 and NRF2, suggesting an enhanced neuroprotective and antioxidant response. Conversely, NF-κB p65 and Bax levels were notably decreased, indicating a suppression of inflammatory and apoptotic pathways. Additionally, Bcl2 expression was significantly increased, highlighting a shift toward cell survival mechanisms. Conclusion: Our findings demonstrate that PEPITEM exerts a multifaceted therapeutic effect in the EAE model of MS by mitigating the symptoms of EAE as evidenced by modulating crucial biomarkers involved in neuroprotection, inflammation, and apoptosis. The significant alterations in the expression of the biomarkers highlight the potential of PEPITEM as a promising therapeutic agent for MS, offering insights into its mechanism of action and paving the way for future clinical investigations.

Keywords:

multiple sclerosis PEPITEM neuroinflammation apoptosis EAE model biomarkers SIRT1 NRF2 NF-κB Bax Bcl2

References

  1. Bohlega S, Inshasi J, Tahan AR, et al. Multiple sclerosis in the Arabian Gulf countries: a consensus statement. Journal of Neurology. 2013; 260(12): 2959-2963. doi: 10.1007/s00415-013-6876-4
  2. Charabati M, Wheeler MA, Weiner HL, et al. Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell. 2023; 186(7): 1309-1327. doi: 10.1016/j.cell.2023.03.008
  3. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F and Weinstock-Guttman B. Multiple sclerosis. Lancet. 2024; 403: 183-202. https://doi.org/10.1016/S0140-6736(23)01473-3
  4. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023; 22: 268-282. https://doi.org/10.1016/S1474-4422(22)00431-8
  5. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023; 402: 2034-2044. https://doi.org/10.1016/S0140-6736(23)01126-1
  6. Liu W, Yu Z, Wang Z, et al. Using an animal model to predict the effective human dose for oral multiple sclerosis drugs. Clinical and Translational Science. 2022; 16(3): 467-477. doi: 10.1111/cts.13458
  7. Jiang Q, Duan J, Kaer LV, et al. The Role of Myeloid-Derived Suppressor Cells in Multiple Sclerosis and Its Animal Model. Aging and disease. Published online 2023: 0. doi: 10.14336/ad.2023.0323-1
  8. Constantinescu CS, Farooqi N, O’Brien K, et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacology. 2011; 164(4): 1079-1106. doi: 10.1111/j.1476-5381.2011.01302.x
  9. Alassiri M, Al Sufiani F, Aljohi M, et al. PEPITEM Treatment Ameliorates EAE in Mice by Reducing CNS Inflammation, Leukocyte Infiltration, Demyelination, and Proinflammatory Cytokine Production. International Journal of Molecular Sciences. 2023; 24(24): 17243. doi: 10.3390/ijms242417243
  10. Chimen M, McGettrick HM, Apta B, et al. Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature Medicine. 2015; 21(5): 467-475. doi: 10.1038/nm.3842
  11. Pezhman L, Hopkin SJ, Begum J, et al. PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology. 2023; 212(1): 1-10. doi: 10.1093/cei/uxad022
  12. Kemble S, Harford L, McGettrick H. O013 New therapeutic avenues in rheumatoid arthritis: exploring the role of the adiponectin-pepitem axis. Oral presentations. Published online February 21, 2018. doi: 10.1136/annrheumdis-2018-ewrr2018.13
  13. Lewis JW, Frost K, Neag G, et al. Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss. Cell Reports Medicine. 2024; 5(5): 101574. doi: 10.1016/j.xcrm.2024.101574
  14. Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy. 2020; 5(1). doi: 10.1038/s41392-020-0110-5
  15. Mohamed GA, Ibrahim SRM, El-Agamy DS, et al. Cucurbitacin E glucoside alleviates concanavalin A-induced hepatitis through enhancing SIRT1/Nrf2/HO-1 and inhibiting NF-ĸB/NLRP3 signaling pathways. Journal of Ethnopharmacology. 2022; 292: 115223. doi: 10.1016/j.jep.2022.115223
  16. Wei L, Zhang W, Li Y, et al. The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence. Frontiers in Cell and Developmental Biology. 2022; 10. doi: 10.3389/fcell.2022.986511
  17. George M, Tharakan M, Culberson J, et al. Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases. Ageing Research Reviews. 2022; 82: 101756. doi: 10.1016/j.arr.2022.101756
  18. Barnabei L, Laplantine E, Mbongo W, et al. NF-κB: At the Borders of Autoimmunity and Inflammation. Frontiers in Immunology. 2021; 12. doi: 10.3389/fimmu.2021.716469
  19. Kielbassa K, Van der Weele L, Voskuyl A, et al. Differential expression pattern of Bcl-2 family members in B and T cells in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Research & Therapy. 2023; 25(1). doi: 10.1186/s13075-023-03203-7
  20. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science. 1999; 286(5445): 1735-1738. doi: 10.1126/science.286.5445.1735
  21. Asadi S, Khabbazi A, Alipour S, et al. Promoter methylation of Bax and Bcl2 genes and their expression in patients with Behcet’s disease. International Journal of Immunogenetics. 2020; 47(3): 309-317. doi: 10.1111/iji.12473
  22. Musella A, Gentile A, Rizzo FR, et al. Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Frontiers in Aging Neuroscience. 2018; 10. doi: 10.3389/fnagi.2018.00238
  23. Khan AW, Farooq M, Hwang MJ, et al. Autoimmune Neuroinflammatory Diseases: Role of Interleukins. International Journal of Molecular Sciences. 2023; 24(9): 7960. doi: 10.3390/ijms24097960
  24. Sinner P, Peckert-Maier K, Mohammadian H, et al. Microglial expression of CD83 governs cellular activation and restrains neuroinflammation in experimental autoimmune encephalomyelitis. Nature Communications. 2023; 14(1). doi: 10.1038/s41467-023-40370-2
  25. Li X, Feng Y, Wang XX, et al. The Critical Role of SIRT1 in Parkinson’s Disease: Mechanism and Therapeutic Considerations. Aging and disease. 2020; 11(6): 1608. doi: 10.14336/ad.2020.0216
  26. Tonev D, Momchilova A. Oxidative Stress and the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Pathway in Multiple Sclerosis: Focus on Certain Exogenous and Endogenous Nrf2 Activators and Therapeutic Plasma Exchange Modulation. International Journal of Molecular Sciences. 2023; 24(24): 17223. doi: 10.3390/ijms242417223
  27. Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy. 2017; 2(1). doi: 10.1038/sigtrans.2017.23
  28. Yan J, Winterford CM, Catts VS, et al. Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology. 2018; 320: 111-116. doi: 10.1016/j.jneuroim.2018.04.002
  29. Sharief MK, Douglas M, Noori M, Semra YK. The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis. Journal of Neuroimmunol. 2002; 125: 155-162. doi: 10.1016/S0165-5728(02)00024-3